J Waskowski1, J C Schefold2, F Stueber3. 1. Universitätsklinik für Anästhesiologie und Schmerztherapie, Inselspital, Universitätsspital Bern, Universität Bern, 3010, Bern, Schweiz. jan.waskowski@insel.ch. 2. Universitätsklinik für Intensivmedizin, Inselspital, Universitätsspital Bern, Universität Bern, 3010, Bern, Schweiz. 3. Universitätsklinik für Anästhesiologie und Schmerztherapie, Inselspital, Universitätsspital Bern, Universität Bern, 3010, Bern, Schweiz.
Abstract
BACKGROUND: Minimising perioperative bleeding is a key goal of "patient blood management" programs. One component of respective strategies includes preventive inhibition of fibrinolysis using protease inhibitors, such as tranexamic acid (TXA). TXA inhibits plasminogen activation and plasmin-induced fibrin degradation. OBJECTIVES: The present article provides an overview of the existing literature and TXA applications in the prophylaxis of perioperative bleeding. METHODS: Literature search in PubMed/MEDLINE (U.S. National Library of Medicine®, Bethesda, MD, USA). RESULTS: TXA reduces perioperative blood loss and transfusion requirements in several randomized controlled trials (RCTs) and meta-analyses in the field of hip and knee arthroplasty for both intravenous and topical use. Moreover, evidence favours use of TXA in complex spine surgery and reconstructive surgery (e. g. craniosynostosis in children). Single RCTs showed benefits of TXA in abdominal hysterectomy, open prostatectomy, liver surgery and actively bleeding trauma patients. For prophylaxis of peripartum haemorrhage (PPH) following vaginal delivery or Caesarean section, TXA cannot be routinely recommended, although evidence points to benefits in actively bleeding patients. A recommendation exists for the treatment of (active) PPH. For prophylactic perioperative administration, different dosage regimens exist for adults. Most often an initial i. v. bolus of 1 g or 10-15 mg/kg body weight with/without repetition after 6 h or continuous infusions over 8 h is administered. Increased rates of thromboembolic events were not noted. CONCLUSION: Protease inhibitors such as TXA reduce perioperative blood loss and transfusion requirements in selected surgical fields.
BACKGROUND: Minimising perioperative bleeding is a key goal of "patient blood management" programs. One component of respective strategies includes preventive inhibition of fibrinolysis using protease inhibitors, such as tranexamic acid (TXA). TXA inhibits plasminogen activation and plasmin-induced fibrin degradation. OBJECTIVES: The present article provides an overview of the existing literature and TXA applications in the prophylaxis of perioperative bleeding. METHODS: Literature search in PubMed/MEDLINE (U.S. National Library of Medicine®, Bethesda, MD, USA). RESULTS:TXA reduces perioperative blood loss and transfusion requirements in several randomized controlled trials (RCTs) and meta-analyses in the field of hip and knee arthroplasty for both intravenous and topical use. Moreover, evidence favours use of TXA in complex spine surgery and reconstructive surgery (e. g. craniosynostosis in children). Single RCTs showed benefits of TXA in abdominal hysterectomy, open prostatectomy, liver surgery and actively bleeding traumapatients. For prophylaxis of peripartum haemorrhage (PPH) following vaginal delivery or Caesarean section, TXA cannot be routinely recommended, although evidence points to benefits in actively bleedingpatients. A recommendation exists for the treatment of (active) PPH. For prophylactic perioperative administration, different dosage regimens exist for adults. Most often an initial i. v. bolus of 1 g or 10-15 mg/kg body weight with/without repetition after 6 h or continuous infusions over 8 h is administered. Increased rates of thromboembolic events were not noted. CONCLUSION: Protease inhibitors such as TXA reduce perioperative blood loss and transfusion requirements in selected surgical fields.
Authors: Daryl L Reust; Scott T Reeves; James H Abernathy; Jennifer A Dixon; William F Gaillard; Rupak Mukherjee; Christine N Koval; Robert E Stroud; Francis G Spinale Journal: Anesth Analg Date: 2010-03-01 Impact factor: 5.108
Authors: Michael Engel; Jens P Bodem; Cornelius J Busch; Dominik Horn; Christian Mertens; Jürgen Hoffmann; Christian Freudlsperger Journal: J Craniomaxillofac Surg Date: 2015-05-29 Impact factor: 2.078
Authors: Enrique Gomez-Barrena; Miguel Ortega-Andreu; Norma G Padilla-Eguiluz; Hanna Pérez-Chrzanowska; Reyes Figueredo-Zalve Journal: J Bone Joint Surg Am Date: 2014-12-03 Impact factor: 5.284